Business Context and Reporting Period
Company: TECHNE Corporation (BIO-TECHNE Corp)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended June 30, 2008
Business Overview: The Company develops and manufactures biotechnology products (cytokines, antibodies, assay kits) and hematology calibrators and controls. Operations are conducted through three reportable segments: Biotechnology (domestic and international), R&D Systems Europe, and Hematology. The Company serves the biotechnology research and clinical diagnostics markets globally.
Key Financial Metrics
| Metric | Fiscal 2008 | Fiscal 2007 | Fiscal 2006 |
|---|---|---|---|
| Net Sales | $257.4 million | $223.5 million | $202.6 million |
| Gross Margin | 79.5% | 79.1% | 77.4% |
| Operating Income | $144.3 million | $124.2 million | $108.5 million |
| Net Earnings | $103.6 million | $85.1 million | $73.4 million |
| Diluted EPS | $2.64 | $2.15 | $1.85 |
| Cash from Operations | $115.3 million | $90.5 million | $85.6 million |
| Cash & Investments | $293.7 million | $256.2 million | $108.8 million |
| Long-Term Debt | $0 | $0 | $12.2 million |
| Current Ratio | 12.77 | 12.38 | 8.34 |
Material Changes vs. Prior Period
- Revenue Growth: Consolidated net sales increased 15.2% to $257.4 million. Growth was driven by increased sales volume across all segments and favorable foreign currency exchange rates (primarily British pound and Euro), which contributed $6.4 million to sales.
- Profitability: Net earnings increased 21.7% to $103.6 million. Gross margins improved to 79.5%, aided by higher margins in the R&D Europe segment due to currency strength and a shift in sales mix toward higher-margin biotechnology products.
- Segment Performance:
- Biotechnology: Sales up 13.0% to $165.7 million, driven by volume and increased sales to diagnostic customers.
- R&D Europe: Sales up 22.6% to $75.7 million (12.2% organic growth).
- Hematology: Sales up 6.1% to $16.0 million.
- Debt Reduction: The Company paid off its remaining mortgage debt in fiscal 2007 and had no long-term debt outstanding as of June 30, 2008.
- Stock Repurchases: The Company repurchased and retired 899,000 shares of common stock for $58.7 million in fiscal 2008 under a $150 million authorization.
Guidance, Outlook, Risks, and Unusual Items
- Outlook: Management expects to meet future capital requirements through cash on hand and operating cash flow. Capital expenditures for fiscal 2009 are estimated at $6.7 million. The Company anticipates an effective tax rate of 33.0% to 34.0% for fiscal 2009.
- Unusual Items:
- Impairment Loss: The Company recorded a $400,000 impairment loss on its investment in Immunicon Corporation (IMMC) following IMMC's Chapter 11 bankruptcy filing.
- Auction-Rate Securities: Due to market failures in February 2008, the Company reduced the value of its auction-rate securities by $2.9 million. These are classified as temporarily impaired and held in accumulated other comprehensive income, not charged to earnings.
- Risks:
- Foreign Currency: Approximately 31% of sales are in foreign currencies; fluctuations in the British pound, Euro, and Chinese yuan impact results.
- Research Spending: Revenues are dependent on spending by pharmaceutical, biotechnology, and academic research institutions.
- Intellectual Property: The Company faces patent infringement litigation from Streck Laboratories regarding hematology controls, though management does not expect a material financial impact.
- Investments: The Company holds significant equity investments in early-stage companies (ChemoCentryx, Hemerus, Nephromics, ACTGen) which carry risks of impairment if those companies fail to secure funding or regulatory approval.
Investor Verification Checklist
- Investment Portfolio Valuation: Verify the status and valuation of the $126.7 million investment portfolio, specifically the $5.8 million in auction-rate securities and the $14.3 million investment in ChemoCentryx.
- Foreign Currency Exposure: Assess the sensitivity of future earnings to fluctuations in the British pound and Euro, given that 31% of sales are foreign.
- Inventory Reserves: Review the $16.0 million reserve for excess protein and antibody inventory and the two-year usage forecast methodology.
- Legal Proceedings: Monitor the outcome of the patent interference proceeding with Streck Laboratories regarding reticulocyte technology.
- Equity Method Investments: Track the financial health of unconsolidated investees (Hemerus, Nephromics, ACTGen) to assess potential future impairment charges.